[Diffusion of cefotaxime in different tissues of the urogenital tract (author's transl)].
Within the framework of perioperative prophylaxis against infections, serum and tissue concentrations were measured following an i. v. bolus injection of 2.0 g of cefotaxime in 25 patients with a prostatic adenoma. The mean serum concentrations were 64.9 microgram/ml, 56.6 microgram/ml, 45.2 microgram/ml, 18.2 microgram/ml and 19.9 microgram/ml 30, 60, 90, 120 and 150 minutes respectively following the injection. The corresponding concentrations in the prostatic adenoma tissue were 8.8 microgram/g, 15.3 microgram/g, 22.9 microgram/g, 4.3 microgram/g and 2.7 microgram/g respectively. The tissue concentrations in ten testes from six patients were measured in a similar way. The maximum concentration (5.4 microgram/g) was also found to occur 90 minutes after the injection. We found very different values, ranging from 0.3 microgram/g to 39.6 microgram/g, in eight kidneys as a result of greatly differing diagnoses and function. Average concentrations of 9.2 microgram/g to 0.8 microgram/g in the ureter, fatty tissue and muscle tissue were within the therapeutically effective range. The cefotaxime concentrations found in serum and tissue lead us to expect successful therapy when cefotaxime is used to treat bacterial infections with sensitive pathogens in the urogenital tract.
D000236:Adenoma / Q000188:drug therapy; D000368:Aged; D002439:Cefotaxime; D002511:Cephalosporins / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D005837:Genitalia, Male / Q000032:analysis*; D006801:Humans; D007668:Kidney / Q000032:analysis; D008297:Male; D011467:Prostate / Q000032:analysis; D011471:Prostatic Neoplasms / Q000032:analysis / Q000188:drug therapy; D013737:Testis / Q000032:analysis; D014018:Tissue Distribution; D014513:Ureter / Q000032:analysis; D014551:Urinary Tract / Q000032:analysis*
D002511:Cephalosporins; D002439:Cefotaxime
Zur Diffusion von Cefotaxim in verschiedene Gewebe des urologischen Bereichs.